Thyrocare Technologies Limited (THYROCARE) retraced post-breakout gains, pulling back by -7% to ₹596.65 on the NSE on 13 Aug 2026. This move comes after the stock cleared its 6-month resistance level at ₹566, marking a breakout. Today’s decline appears to be profit-taking following this breakout. Thyrocare, a prominent player in the diagnostics and research sector, has seen its stock move independently of broader sector trends, driven by company-specific news and chart dynamics.

Technical setup — trendlines & DMA

From a technical standpoint, Thyrocare’s current price is comfortably above its 6-month support trendline at ₹507.25, indicating a robust uptrend. The stock has broken through its 6-month resistance at ₹565.92, confirming a breakout. However, it is currently trading 17% above its 50-day moving average (DMA) at ₹551.7, suggesting the stock is extended. Despite this, the 50-DMA remains above the 200-DMA at ₹461.3, reinforcing the bullish trend. Thyrocare’s price is in the upper third of its 52-week range, reflecting a significant portion of its annual move has already been priced in.

Fundamentals & business context

On the fundamental front, Thyrocare’s PE of 58.4, coupled with a profit margin of 20.1% and a revenue CAGR of 16.7%, suggests the market is pricing in robust growth expectations. The company’s strong revenue and profit CAGRs over the past five years indicate a business in expansion mode. With 22.0% institutional ownership, Thyrocare is viewed favorably by sophisticated investors. Today’s move appears driven by chart dynamics and profit-taking post-breakout rather than any fresh news from the NSE.

Algorithmic scorecard

Thyrocare’s algorithmic scorecard reflects a balanced but slightly technically tilted profile. The stock’s bullish trend, indicated by the 50-DMA above the 200-DMA, and its strong position above both moving averages, suggest sustained upward momentum. Additionally, the stock’s low beta of 0.50 points to lower volatility and market risk, making it a stable pick in the sector. On the flip side, the stock’s valuation, while reasonable with a PEG of 1.41, and its moderate dividend yield of 2.93% indicate there may be limited upside from income generation alone. Investors should weigh these factors carefully.

Company outlook

Thyrocare’s management has outlined a positive outlook for the coming fiscal year. They are maintaining mid to high teens guidance for franchisee growth for FY27 and expect to see improvement in revenue per test as the test menu widens. The specialty segment is anticipated to reach 15-20% of the portfolio in 3-5 years. Management expects EBITDA margins to remain in line with current levels as the specialty segment grows. Additionally, the company plans to continue adding franchisees, with a revised target of around 1,700 franchisees in FY27. These initiatives underscore Thyrocare’s commitment to expanding its footprint and enhancing its service offerings.

Get all details on THYROCARE — P&L, peers, shareholding and more on TradeAlone.

Vijaya Diagnostic Centre Limited (VIJAYA) breaks out with a +5% gain to ₹1502.0 on the NSE, clearing its 6-month resistance trendline. This move follows the company’s recent concall, where robust Q1 FY27 results were discussed, fueling post-concall momentum. VIJAYA operates in the diagnostics and research sector, and today’s breakout indicates strong company-specific performance rather than broad sector momentum.

Technical setup — trendlines & DMA

VIJAYA’s current 6-month trendline structure shows a breakout above the resistance at ₹1431.53, with the stock now trading 4.69% above this level. The 6-month support trendline stands at ₹1333.73, indicating a solid floor 11.20% below the current price. The 50-DMA at ₹1342.4 is above the 200-DMA at ₹1108.7, signaling a bullish trend. The stock is in the upper third of its 52-week range, up 110% from the 52-week low and just 4.2% below the 52-week high, suggesting that much of the upward momentum is already priced in.

Fundamentals & business context

With a PE of 78.3 and profit margins at 21.9%, VIJAYA’s valuation appears stretched relative to its current earnings, though its revenue CAGR of 21.1% indicates strong growth potential. The company’s PEG ratio of 2.91 suggests it is overvalued compared to its growth rate. Institutional ownership stands at 38.8%, reflecting confidence among sophisticated investors. There is no new NSE catalyst today, but the recent concall highlighted solid financial performance and growth prospects.

Algorithmic scorecard

VIJAYA’s overall algorithmic scorecard of 78 reflects a balanced but slightly technically weaker profile. The strongest signals are its excellent revenue and profit CAGRs, indicating robust growth, and its low debt levels, showcasing a strong balance sheet. On the weaker side, the stock’s PEG ratio suggests it is overvalued relative to its growth rate, and its negligible dividend yield offers little income to investors. These factors highlight both the growth potential and the valuation risks associated with the stock.

Company outlook

VIJAYA’s recent concall revealed several strengths, including solid year-on-year revenue growth of 22.8% in Q1 FY27, volume growth of 16.5%, and a healthy EBITDA margin of 42.7%. The company is also expanding its network with advanced imaging technologies and new centres. However, there were minor weaknesses such as a small EBITDA loss from new centres and flat growth in the Pune geography. Overall, the concall painted a picture of a company on a growth trajectory with some minor operational challenges.

Management’s outlook for VIJAYA is optimistic, with expectations to maintain an EBITDA margin above 40% and achieve high double-digit growth for FY27. The company plans to commission additional hub and spoke centres and invest in land acquisition in Andhra Pradesh. Capex is expected to be around ₹190 crores to ₹195 crores. Management is confident in sustaining 15% growth over the next 3 to 5 years, driven by network expansion and continued leadership in imaging and pathology.

Get all details on VIJAYA — P&L, peers, shareholding and more on TradeAlone.

Syngene International Limited (SYNGENE) breaks below support, falling -8% to ₹380.1 on the NSE on 30 Jul 2026, backed by its Q1 FY27 results showing a 16% drop in revenue to Rs. 736 crore and a 56% decline in operating EBITDA to Rs. 91 crore. This move comes amid a broader sectoral slowdown in diagnostics and research, with Syngene’s performance reflecting company-specific challenges rather than sector-wide momentum.

Technical setup — trendlines & DMA

The current trendline structure for Syngene shows a breakdown below the 6M support trendline, which ended at ₹395.22, now 3.98% above the current price. Resistance remains at ₹424.73, which is 11.74% above the current price. The 50-DMA at ₹436.5 is below the 200-DMA at ₹504.3, indicating a bearish trend. The stock is currently in the lower third of its 52-week range, suggesting that much of the recent downward move may already be priced in, though the significant gap from the 52-week high indicates potential for further downside.

Fundamentals & business context

With a PE of 52.7, Syngene’s valuation appears stretched given its current profit margin of 8.5% and a revenue CAGR of 5.4% over the last five years. The market seems to be pricing in potential future growth, despite the recent decline in profitability. Institutional ownership stands at 38.4%, suggesting that despite the recent performance, smart money still sees value in the company. There is no new NSE catalyst today beyond the Q1 FY27 results.

Algorithmic scorecard

Syngene’s overall algorithmic score reflects a company with strong fundamental attributes but weak technical performance. The strongest signals include very low debt, indicated by a D/E ratio of 0.00, and consistent revenue growth every year, showcasing exceptional business stability. However, the weakest signals are the declining profit CAGR of -12.0% and the negligible dividend yield of 0.31%, which could pose risks to long-term investor returns. Additionally, the stock’s bearish trend, as evidenced by the 50-DMA being below the 200-DMA, and its poor performance over the last year, with a decline of 42.5%, highlight the technical challenges facing the stock.

Company outlook

Management expects a broadly flat performance for FY27, with EBITDA margins maintained in the mid-20s. The first half of FY27 is anticipated to be muted, with a stronger second half. The impact of Librela is expected to be most significant in the first two quarters of FY27, after which the company should return to a growth trajectory. Sustained growth is projected from FY28 onwards as new capabilities and pipelines mature. This outlook suggests that while the near-term may remain challenging, the company is positioning itself for stronger performance in the medium to long term.

Get all details on SYNGENE — P&L, peers, shareholding and more on TradeAlone.